从相关性到因果关系:在阿尔茨海默病中细胞类型特定的基因调节网络
Danni Liu1,2, Zhongli Jiang1, Hyunjin Kim3
1Department of Epidemiology and Biostatistics, University of California, Irvine, California, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 12, 2026
概括
这项研究在特定的大脑细胞类型中绘制了阿尔茨海默病 (AD) 基因调节网络 (GRNs),揭示了超越转录因子 (TF) 的复杂调节机制,并为其他疾病提供了框架.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 系统生物学 系统生物学
背景情况:
- 阿尔茨海默氏病 (AD) 的发病过程涉及不同类型的大脑细胞的复杂调节性干扰.
- 潜在的AD细胞内因果机制仍然不完全理解.
研究的目的:
- 在阿尔茨海默病 (AD) 中构建全面的,细胞类型特定的基因调控网络 (GRNs).
- 为了确定因果调节关系和关键调节基因在不同的脑细胞类型中受影响的AD.
- 开发适用于复杂疾病的综合性分析框架.
主要方法:
- 利用单核转录组学和匹配的基因型数据来自272名AD患者 (ROSMAP队列).
- 开发了一个基于因果关系的框架来构建特定于细胞类型的GRNs.
- 确定了调节基因,包括转录因子 (TFs) 和非TFs,并评估了它们的作用 (调节者与目标).
主要成果:
- 在AD中生成了六种脑细胞类型的全面因果调节图.
- 确定了已知的和新的调节途径,枢纽基因和AD脑细胞特有的功能模块.
- 揭示了涉及非TF基因和相互连接的TF模块的复杂监管机制,超越了以TF为中心的模型.
结论:
- 这项研究为AD提供了详细的,细胞类型特定的因果GRN,为细胞功能和疾病机制提供了洞察力.
- 开发的方法适用于分析癌症等复杂疾病,促进途径探索和假设生成.
- 这些发现凸显了AD病原性中复杂的,非TF介导的监管复杂性.
相关概念视频
01:37Neural Regulation
34.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.8K
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
38
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38
01:23Alzheimer Disease ll: Pathophysiology
44
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
44
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35